NCT07558616 Study on the Clinical Efficacy of Transcranial Strong Alternating Current (Hi-tACS) in Patients With Neuroimmune Diseases With Insomnia
| NCT ID | NCT07558616 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Neuroimmune Diseases With Insomnia |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-09-01 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to comprehensively evaluate the therapeutic effects of high-intensity transcranial alternating current stimulation (hi-tACS) on insomnia symptoms in patients with idiopathic inflammatory demyelinating disorders (IIDDs) by analyzing both the overall disease characteristics of IIDDs and individual patient variability. Additionally, the study will investigate the neuroimmunomodulatory mechanisms of hi-tACS. The findings are expected to provide evidence for the clinical application of hi-tACS in managing insomnia in IIDDs and offer new insights for personalized treatment strategies.
Eligibility Criteria
Inclusion Criteria: 1. Patients with idiopathic inflammatory demyelinating disorders (IIDDs) meeting the diagnostic criteria, including neuromyelitis optica spectrum disorders (NMOSD) \[based on the Chinese Guidelines for Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (2016 Edition)\] and multiple sclerosis (MS) \[based on the Chinese Guidelines for Diagnosis and Treatment of Multiple Sclerosis (2023 Edition)\], and accompanied by insomnia. * Aged between 18 and 65 years, regardless of gender. * Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months. * Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 \[daytime dysfunction\] ≥2). * Having not taken hypnotics or insomnia treatment medication for at least 4 months. * Female participants aged 18-50 years who agree to use effective contraception throughout the study period. * Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period. * Agree to participate and sign the informed consent. 2. Patients diagnosed with chronic primary insomnia according to 《The Diagnostic and Statistical Manual of Mental Disorders》(Text Revision) (DSM-IV-TR) or 《International Classification of Diseases Tenth Revision》(ICD-10): * Aged between 18 and 65 years, regardless of gender. * Experiencing difficulty falling asleep, difficulty maintaining sleep, or early morning awakening on at least 3 nights per week for more than 3 months. * Severe daytime functional impairment (Chinese version of the Pittsburgh Sleep Quality Index, item 7 \[daytime dysfunction\] ≥2). * Having not taken hypnotics or insomnia treatment medication for at least 4 months. * Female aged 18\~50 years agreeing to adopt birth control measures during the study period. * Agreeing to refrain from receiving medication or other non-pharmacological treatments during the study period. * Agree to participate and sign the informed consent. Exclusion Criteria: * History of relapse within the past 1 month. * Drug adjustment within the past 1 month, or receipt of modified electroconvulsive therapy, transcranial magnetic stimulation therapy, or other neuralcontroltechnology therapy. * Participation in any other clinical studies within 1 month prior to enrollment or currently. * Presence of cochlear implant system, cardiac-pacemaker, or intracerebral implanted stimulators. * Impaired skin integrity at the electrode placement site, or allergy to electrode gel or adhesive. * History of organic brain diseases such as epilepsy, hydrocephalus, tumor of central nervous system, craniocerebral injury, or intracranial infection. * Pregnant or lactating women, or those intending pregnancy soon; * A score of ≥3 on the suicide item of the Hamilton Depression Scale, or coexisting severe mental disorders; * Presence of severe or unstable organic diseases; * Work night shifts; * Presence of other sleep disorders; * Poor patient compliance preventing cooperation with treatment, follow-up, or clinical, electroencephalographic (EEG), or imaging data collection; * Other circumstances deemed by the investigator as inappropriate for study participation.
Contact & Investigator
Junwei Hao
PRINCIPAL INVESTIGATOR
Department of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China
Frequently Asked Questions
Who can join the NCT07558616 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Neuroimmune Diseases With Insomnia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07558616 currently recruiting?
Yes, NCT07558616 is actively recruiting participants. Contact the research team at zyn1616@xwhosp.org for enrollment information.
Where is the NCT07558616 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07558616 clinical trial?
NCT07558616 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Junwei Hao at Department of Neurology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing, China. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.